US acquisition of Rosemont Pharmaceuticals

Published: 1-Nov-2002


US-based Bio-Technology General Corporation (BTG) has completed its £61m (US$94m) purchase of Rosemont Pharmaceuticals, based in Leeds in the UK. Rosemont is a subsidiary of Akzo Nobel and a leader in the UK market for oral liquid formulations of branded non-proprietary drugs. The acquisition provides BTG with a valuable presence in the European specialty pharmaceutical marketplace, according to Sim Fass, BTG chairman and ceo.

Products manufactured and marketed by Rosemont include CNS and cardiovascular drugs and a recently introduced patented oral liquid formulation of tamoxifen, trademarked Soltamox, for the treatment of breast cancers. Global rights to the tamoxifen product are also included in the acquisition.

You may also like